ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Inflectra®:Pfizer PFE Switzerland GmbH
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
L04AB02 - InfliximabATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L04 - Immunosuppressants

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.

L04A - Immunosuppressants

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.

L04AB - Tumor Necrosis Factor Alpha (Tnf-Α) Inhibitors
 

The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.

L04AB02 - Infliximab
Concentr.Adm.RouteNote
3.75 mgP 
2020 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home